Beam Therapeutics Inc.
BEAM
$23.91
$0.944.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.90% | -82.38% | -83.18% | 328.73% | 339.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.90% | -82.38% | -83.18% | 328.73% | 339.83% |
| Cost of Revenue | -18.19% | -35.21% | -46.92% | -29.42% | -25.02% |
| Gross Profit | -318.44% | -3,113.22% | -182.60% | 126.10% | 126.32% |
| SG&A Expenses | -12.03% | -6.09% | -4.53% | 31.05% | 34.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.73% | -8.90% | -13.55% | 10.93% | 16.35% |
| Operating Income | -141.81% | -137.07% | -135.47% | 54.14% | 51.64% |
| Income Before Tax | -181.47% | -190.40% | -187.21% | 54.53% | 56.26% |
| Income Tax Expenses | -100.00% | -97.14% | -97.14% | 40.50% | -58.80% |
| Earnings from Continuing Operations | -178.71% | -187.48% | -184.28% | 54.22% | 56.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.71% | -187.48% | -184.28% | 54.22% | 56.29% |
| EBIT | -141.81% | -137.07% | -135.47% | 54.14% | 51.64% |
| EBITDA | -160.31% | -154.02% | -151.57% | 57.65% | 55.31% |
| EPS Basic | -155.64% | -164.76% | -144.95% | 58.80% | 60.96% |
| Normalized Basic EPS | -183.86% | -157.45% | -156.13% | 65.70% | 69.07% |
| EPS Diluted | -149.93% | -158.78% | -139.79% | 57.80% | 60.05% |
| Normalized Diluted EPS | -176.94% | -151.73% | -150.40% | 64.84% | 68.30% |
| Average Basic Shares Outstanding | 9.67% | 5.54% | 6.73% | 9.67% | 11.79% |
| Average Diluted Shares Outstanding | 9.05% | 4.93% | 6.09% | 10.29% | 12.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |